SanBio, Inc.

37 articles about SanBio, Inc.

• Bijan Nejadnik, M.D., Appointed as Chief Medical Officer of SanBio

  5/15/2019

  The SanBio Group announced the appointment of Bijan Nejadnik, M.D., as its new Chief Medical Officer in charge of development and regulatory affairs.

• SanBio: SB623, an Investigational Product, Granted Advanced Therapy Medicinal Product Classification by European Medicines Agency

  4/25/2019

  he SanBio Group announced that Advanced Therapy Medicinal Product (ATMP) classification has been granted for SB623 for the treatment of patients with motor deficits arising from Acquired Brain Injury, including traumatic brain injury, ischemic stroke and haemorrhagic stroke.

• AANS 2019: SB623 Demonstrated Statistically Significant Improvement in Motor Function Among Patients with Chronic Motor Deficit from Traumatic Brain Injury (TBI)

  4/16/2019

  Positive results from the STEMTRA Phase 2 trial were presented today at the American Association of Neurological Surgeons (AANS) annual scientific meeting

• SanBio Announces SB623 Regenerative Cell Therapy for Traumatic Brain Injury Has Received Ministry of Health, Labour and Welfare (MHLW) Sakigake Designation

  4/8/2019

  The SanBio Group announced that SB623, a regenerative cell therapy that the Group is developing globally for the treatment of chronic motor deficit resulting from traumatic brain injury (TBI), has received the Sakigake Designation for innovative medical products from the Ministry of Health, Labour, and Welfare (MHLW) of Japan.

• SanBio: Addition of a Cerebral Hemorrhage Program for SB623 Regenerative Cell Medicine

  1/21/2019

  At a meeting held today, the Board of Directors of SanBio Co., Ltd. (hereinafter, the “Company”) resolved to add a program for treatment of chronic motor deficit from cerebral hemorrhage as a new indication for SB623, a regenerative cell medicine developed by the Group.

• SanBio, Inc. Names Mohammad El-Kalay New Technical Operations SVP

  9/25/2017

• SanBio, Inc. Receives $20 Million Grant From CIRM For Stroke Clinical Trial

  7/5/2017

• Study Of SanBio, Inc.'s Stem Cell Treatment For Stroke Receives Innovation Award From AHA

  2/27/2017

• SanBio, Inc. Granted Key Patent In Treatment For Traumatic Brain Injury

  11/9/2016

• SanBio, Inc. Presents Interim Results Of The First Intracerebral Stem Cell Transplant Study For Stroke In The United States

  11/7/2016

• SanBio, Inc. Release: First Patient Is Enrolled In Global STEMTRA Trial For Traumatic Brain Injury In Japan

  10/26/2016

• SanBio, Inc. Begins Clinical Trial Of Regenerative Cell Medicine For Patients With Traumatic Brain Injury In Japan

  9/21/2016

• SanBio, Inc. Names Greg Gillas New SVP Of Human Resources And Corporate Services

  9/7/2016

• SanBio, Inc. Release: First Patient Is Randomized In STEMTRA Trial For Traumatic Brain Injury

  7/11/2016

• SanBio, Inc. Presents Interim Results Of Chronic Stroke Phase I/IIa Clinical Trial At International Society Of Stem Cell Research Annual Meeting

  6/24/2016

• SanBio, Inc. Publishes Interim 12-Month Phase 1/2a Clinical Trial Results In The Peer-Reviewed Medical Journal, Stroke

  6/3/2016

• SanBio, Inc. Granted Key Patent In Treatment For Macular Degeneration

  5/16/2016

• SanBio, Inc. Release: Clinical Trial Involving Regenerative Cell Treatment For Patients With Traumatic Brain Injury Permitted In Japan

  4/6/2016

• SanBio, Inc. Names Jay Stout New Manufacturing SVP

  4/1/2016

• SanBio, Inc. Release: University Hospitals Case Medical Center Randomizes The First Patient In Actissima Trial For Chronic Stroke

  3/10/2016